Iparomlimab and Tuvonralimab combined with lenvatinib and SOX
QL-GasC-QIBA-3011
Phase 2 small_molecule active
Quick answer
Iparomlimab and Tuvonralimab combined with lenvatinib and SOX for Gastric or Gastroesophageal Junction Adenocarcinoma is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active